PCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pacira Biosciences Inc (PCRX) is not an ideal buy for a beginner, long-term investor at this moment. While the stock shows some positive technical indicators and hedge fund interest, the company's financial performance is weak, with significant declines in net income and EPS. Additionally, analysts have recently lowered the price target, and the stock's near-term momentum appears limited. The lack of strong proprietary trading signals further supports a cautious approach.
The MACD is positive and expanding (0.0723), suggesting bullish momentum. RSI is neutral at 61.54, and moving averages are converging, indicating no strong directional trend. The stock is trading near its R1 resistance level of 23.784 in pre-market, which could act as a short-term barrier.
Hedge funds are significantly increasing their positions, with a 695.83% increase in buying activity over the last quarter. Gross margin improved by 1.70% YoY to 72.26%.
Analysts have lowered the price target from $27 to $25, citing limited near-term momentum. No significant insider or congress trading activity to indicate confidence.
In Q4 2025, revenue increased by 5.14% YoY to $196.87M, but net income dropped sharply by 89.79% to $1.64M. EPS also fell by 88.57% to $0.04. Gross margin improved slightly to 72.26%, up 1.70% YoY.
Barclays maintains an Equal Weight rating but lowered the price target to $25 from $27, citing limited near-term momentum and pipeline updates weighted toward the back half of the year.
